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Compound X 
Summary. The enantiomeric [1,2-bis(2-hydroxyphenyl)- x@xx/ ?x  1-ptcl 2 4-OH 
ethylenediamine]dichloroplatinum(II) complexes were 
synthesized and their configuration assessed. A prelimi- - -  2_-Ptct2 3-OH 
nary test in the cisplatin-resistant human NIH:OVCAR- 2-0H H2N~ /NH2 3_- P'{:C[2 
3 ovarian cancer cell line, which was previously charac- Pf~cI 
terized by its sensitivity against several therapeutically zI 
used drugs, showed that both enantiomers produce cy- 
tocidal effects in a concentration of 2.5 pM. A difference 
between the enantiomers became vident from the faster 
onset of cytocidal activity of the S,S-configurated com- 
pound. 
Key words: (R,R)- and (S,S)-[l,2-bis(2-hydroxyphenyl)- 
ethylenediamine]dichloroplatinum(II) - Synthesis - 
NIH:OVCAR-3 ovarian cancer cell line - preliminary 
testing 
Introduction 
Among the 1,2-diphenylethylenediamineplatinum(II) 
complexes, [( _+ )-l ,2-bis(2-hydroxyphenyl)ethylenedi- 
amine]dichloroplatinum(II) (Scheme 1: (_+)-3-PtCIE) has 
proved to be a potent cytostatic (Miiller et al. 1990). It is 
noteworthy that (+_)-3-PtC12 is also active in several cis- 
platin-resistant tumor models in cell culture as well as in 
animal experiments. Of special interest are the results of 
in vitro experiments on the human NIH:OVCAR-3 
ovarian cancer cell line, which is described to be resistant 
to clinically relevant concentrations ofAdriamycin, mel- 
phalan and cisplatin. In this trial (___)-3-PtC12 exhibited 
a cytocidal effect at concentrations (2.5 and 5.0 laM) that 
were tolerated without complications in animal experi- 
* Dedicated to Professor J. Knabe on the occasion ofhis 70th birth- 
day 
* * Part I: Mtiller et al. (1990) 
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Scheme 1 
Scheme 1. Structure of 1,2-diphenylethylenediamineplatinum(II) 
complexes compared to eisplatin 
ments. Because of these results we assume that (+)-3- 
PtC12 could be useful for the first-line treatment of 
ovarian cancer in combination with cisplatin to avoid de- 
velopment of resistance, as well as for the second-line 
therapy of the cisplatin-resistant tumor. In this publica- 
tion we report attempts to optimize the effect of (_+)-3- 
PtCI 2 on ovarian carcinoma by resolution of the drug 
into its enantiomers. 
Materials and methods 
Chemical methods 
(--)-  and ( + )-l,2-bis (2-methoxyphenyl) ethylenediamine [ ( - )-3a 
and (+)-3a]: method A. Compound (+)-3a (10.2 g = 37.5 mmol), 
dissolved in 40 ml 82% EtOH, was given to a solution of (R,R(. +)- 
tartaric acid (16.8 g = 112 retool) in 105 ml 82% EtOH and boiled 
under eflux for 10 min. Upon slow cooling (-)-3a-tartrate crystal- 
lized at room temperature. It was recrystallized from 82% EtOH 
several times, treated with 5% NaOH and extracted with EtzO. The 
organic layer was washed with Ha0, dried over MgSO4, and evap- 
orated, to leave a colourless powder: m.p. 77-78 ~ C; yield 15%; 
26 
[a ]546  = - -  124% e= 1.0, MeOH; optical purity ~ 100%. From the 
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filtrates (+_)3a and (+)-3a were isolated and purified in the same 
manner by crystallization as the (S,S)-(-)-tartrate: colourless 
powder; m.p. 70--72 ~ C, yield 31%; [~]~66 = + 118~ c= 1.0, MeOH; 
optical purity ~ 100%. The enantiomeric purity was determined by 
1H-NMR- spectroscopy (250 MHz) by mea0s of the formation of 
diastereoisomeric complexes with (S)-(+)-l-(9-anthryl)-2,2,2-tri- 
fluoroethanol. The molar ratio of this alcohol to (-)-3a and to 
(+)-3a, respectively, was 6.3; the solvent was 0~ 5 ml CDC)3 and two 
drops DzO. The benzylic proton signals of ( - ) -3a are shifted to a 
higher field (6)= 4.12 ppm) than thoseof (+)-3a. (6=4.22 ppm) 
(Fig. 1). The enantiomeric purity of ( - ) -3a and (+)-3a was estab- 
lished by the integral ratio of the two singlets for the benzylic pro- 
tons. 
( - )-1,2-his (2-hydroxyphenyl) ethylenediamine [ ( -)-3]: method B. 
A solution of ( - ) -3a (793 mg= 2.91 ram01) in 70 ml dry CHzC12 
was cooled to -60  ~ C. BBr 3 (2.91 g = 11.63 mmol), dissolved in 
20 ml dry CH2C12, was added in a N 2 atmosphere. The reaction 
mixture was stirred for 3 days under slow warming to room temper- 
ature. Then 250 ml 10% NaOH was added and the polymeric side- 
products were removed by separation of the CH2C12 layer. The 
aqueous phase was neutralized with HC1 (pH8) and ( - ) -3  was ex- 
tracted with ethyl acetate. The organic layer was washed several 
times with water and dried over MgSO4. The solvent was evapo- 
rated under reduced pressure to leave a beige powder: m.p. 156- 
158 ~ C; yield 61%; 26 [~]s46 = - 122~ c = 1.0, MeOH. 
( + )-l,2-bis (2-hydroxyphenyI)ethylenediamine [ ( +)-3] was ob- 
tained as a beige powder: m.p. 151-153 ~C; yield 49%; 26 
+ 125 ~ c = 1.0, MeOH. 
[(--)-  and ( + )-1,2-bis(2-hydroxyphenyl)ethylenediamine]dichIo- 
roplatinum(II) [(-)-3-PtC1 z and ( + )-3-PtClz]: method C. Com- 
pounds (-)-3-PtCI z and (+)-3-PtC12 were prepared according to 
the procedure of Miiller et al. (1990) for (+)-3-PtC12. (-)-3-PtC12 
was obtained as a white powder: yield 77%; 26 [~]54a = - 174~ c = 1.0, 
dimethylformamide. (+)-3-PtC12 was a white powder: yield 69%; 
z6 ["]s46 = + 177~ c = 1.0, dimethylformamide. 
[(+__ )-l,2-bis- (2-hydroxyphenyl) ethylenediamine]diiodoplatinum (II) 
[( +_ )-3-PtI2]. An aqueous olution of KzPtC14 (208 nag, 0.5 retool) 
and KI (0.83 g, 5 mmol) was stirred for 30 min in the dark 
at room temperature. (+)-3 (122 nag, 0.5 mmol) was dissolved 
in 50 ml water by adding 2 M HC1 droPwise. The reaction mixture 
was stirred for 24 h in the dark. The pH was kept between 5.5 and 
6.5. The complex was collected by suction filtration, washed with 
water and dried in vacuo over P205 to leave a yellow powder: yield 
72%. 
[N,N'-tetradeutero ( +.)-l,2-bis- (2-hydroxyphenyI) ethylenedi- 
amine]-sulfatoplatinum(II) [(+_)-3-PtSO,j. (+)-3-PtI 2 (242 rag, 
0.35 mmol) and Ag2SO 4 (93 rag, 0.3 mmol were stirred for 24 h in 
D20 at 40 ~ C with protection from light. The precipitated AgI was 
filtered off and the clear yellow solution was lyophilized to give a 
colourless powder: yield 83%. 
General procedures 
Melting points (uncorrected) were determined on a Bfichi 510 melt- 
ing-point apparatus; for 1H-NMR spectra of the ligands a Varian 
EM 360-L 60-MHz spectrometer was used and the 1H-NMR spec- 
tra of the platinum complexes were received on a Bruker PFR- 
NMR spectrometer WM 250 at 250 MHz. Elemental analyses were 
performed by the microlaboratory of the University of Regensburg. 
For evaluation of the specific rotation we used a Perkin-Elmer 
241 MC p01arimeter. The circular dichroism (CD) spectra were ob- 
tained with a JASCO J-500 A spectropolarimeter (time constant =
4 s; scan speed = 5 nm/min) and recorded in dimethylformamide at 
room temperature in 5.0-cm quartz cells. The concentrations were 
0.1 mM for (-)-3-PtC12 and (+)-3-PtC12. The structure of (--)-3- 
PtC12 was determined using an Enraf-Nonius CAD4 diffractometer 
and program package SDP V 3.1. 
Biological methods 
NIH.'OVCAR-3 ovarian cancer cell line. The NIH:OVCAR-3 
(ATCC no. HTB 161), a human adenocarcinoma of the ovary 
(Hamilton et al. 1983), was obtained from the American Type Cul- 
ture Collection in passage 17. Cell-line banking and quality control 
were performed according to the "seed stock concept" reviewed by 
Hay (1988). The cells were maintained in RPMI-1640 medium 
(Sigma) containing NaHCO3 (2 g/l), gentamicin (50 mg/1), 10% 
Basal Medium Supplement (Seromed) and insulin (10 gg/ml) 
(Sigma) in 75-crn 2flasks at 37 ~ C in a H20-saturated atmosphere of
95% air and 5% CO2. The cells were serially passaged weekly fol- 
lowing trypsinization using trypsin/EDTA (Boehringer). 
For chemosensitivity testing the cells were plated in 96-well 
microplates (100 lal/well at a density of about 17-28 cells/micro- 
scopic field (Leitz Diavert, 320 x ) and were allowed to attach. After 
48-80 h, the medium was removed by suction and replaced with 
fresh medium (200 gl/well) containing drug (drugs were added as a 
1000-fold stock solution) or pure solvent. Clinically established 
chemotherapeutics were dissolved in EtOH, platinum complexes in 
dimethylformamide. On every plate the rows 5 and 6 (n = 16) served 
as controls, whereas two vertical rows (n= 16) per drug concentra- 
tion and time point were used. After various times of incubation the 
cells were fixed with glutardialdehyde and stored under phosphate- 
buffered saline at 4 ~ C. 
All plates were stained with crystal violet simultaneously. The 
processing procedure and data analysis were performed as described 
by Reile et al. (1990). In order to save space, the growth curves of 
the drug-treated cells are not shown. Drug effects were calculated as 
corrected T/C values according to: T/C .... (%) = (T - Co)/(C - 
Co) • 100 where T is the absorbance of treated cells, C the absor- 
bance of the controls and Co the absorbance atthe time (t = 0) when 
drug was added (Bernhardt et al. 1992). According to this equation, 
any growth curve of a drug-treated cell population can be recon- 
structed from the T/C .... profiles (Fig. 10) and the growth curves of 
the corresponding controls hown in Fig. 9. The experimental errors 
for T/C .... range from approximately + 20% after short times of in- 
cubation (small values for T and C) to ___ 5% with prolonged incu- 
bation. 
Cytogenetic analysis. The cells were grown to about 50% confluence 
on microscopic slides. The slides were prepared as described else- 
where (Rooney and Czepulkowski 1986). So that spindle formation 
could be inhibited, the slide chambers were inoculated with col- 
cemid solution (Serva) to a final concentration f 0.04 gg/ml and in- 
cubated for 3 h at 37 ~ C. The medium was removed by suction and 
replaced with 0.075 M KC1. After 30 min of incubation at 37 ~ C an 
equal volume of cold, freshly made fixative (absolute methanol/gla- 
cial acetic acid, 3/1) was added. This hypotonic/fixative mixture was 
removed immediately and replaced twice with ice-cold, fresh fixa- 
tive. The slides were removed from the dish and air-dried at 60 ~ 
The chromosomes were stained for 8 min with 10 ml Giemsa plus 
90 ml 0.025 M KH2PO4, pH 6.8. 
Doubling-time analysis. Curve fitting of experimental data of the 
growth curves was accomplished by a polynomal regression fit 
applying the least-squares method (Reile et al. 1990). 
Results 
Chemistry 
The diastereoisomeric  [1,2-bis-(2-hydroxyphenyl)ethyle-  
ned iamine]d ich lo rop la t inum( l I )  complexes (_+)-3-PtCl 2
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Scheme 2. Synthesis of enantiomeric 3-PtC12 complexes 
and meso-3-PtClz have been described in our preceding 
publication (Miiller et al. 1990). For the synthesis of the 
(+) and ( - )  rotatory [l,2-bis-(2-hydroxyphenyl)ethyle- 
nediamine]dichloroplatinum(II)complexes [(+)-3-PtC12 
and (-)-3-PtClj the resolution into the optically active 
forms was performed at the stage of (+)-l,2-bis-(2-meth- 
oxypenyl)ethylenediamine [(_+)-3a; for the synthesis of 
(+__)-3a compare Miiller et al. (1990)] (Scheme 2). 
The separation i to the enantiomers was achieved by 
fractional crystallization of the diasteroisomeric salts, 
formed by reaction of (+)3a with optically active tartaric 
acid in EtOH (method A). This procedure has been suc- 
cessfully applied several times to 1,2-diphenylethylenedi- 
amines (von Angerer et al. 1982; Wappes et al. 1984; Jen- 
Table 2. [1,2-bis(2-hydroxyphenyl)ethylenediamine]dichloroplati- 
num(II) complexes - analytical data 
Compound C (%) H (%) N (%) 
Calc. Found Calc. Found Calc. Found 
(-)-3-PtClz 33.0 33.3 3.16 3.28 5.5 5.3 
(+)-3-PTC12 33.1 3.19 5.4 
nerwein et al. 1989; vom Orde et al. 1990). The complete 
enantiomeric purity of the diamines (+)-3a and (-)-3a 
could be proved by means of the formation of diastereoi- 
someric omplexes with (S)-(+)-l-(9-anthryl)-2,2,2-tri- 
fluoroethanol. They show different 6values for the ben- 
zylie protons of (+)-3a (4.22ppm) and (-)-3a 
(4.12 ppm) in the 250-MHz 1H-NMR spectra (Fig. 1). 
Ether cleavage of the methoxy compounds (+)-3a 
and (-)-3a with BBr3 leads to the hydroxy derivatives 
(+)-3 and (-)-3 (method B). The dichloroplatinum(II) 
complexes ( +)-3-PtCI2 and (-)-3-PtClz were formed by 
reaction with KzPtC14 (method C). 
The identity and purity of these compounds were con- 
firmed by tH-NMR spectroscopy (Table 1), IR spectros- 
copy and elemental nalyses (Table 2). 
The absolute configuration of the enantiomeric [1,2- 
bis(2-hydroxyphenyl)ethylenediamine] dichloroplati- 
nurn(II) complexes (+)-3-PtC12 and (-)-3-PtC1 zwas de- 
termined by comparison of their CD spectra with those 
of (+)-(R,R)- and (-)-(S,S)-dichloro[1,2-diphenylyleth- 
ylene diamine]platinum(II), the structural assignment of
which derives from the known absolute configuration of
(+)-1,2-diphenylethylenediamine (R,R) (Meric and Vig- 
neron 1974). In analogy to the 3- and 4-hydroxy-substi- 
tuted (+_)-dichloro[l,2-diphenylethylenediamine] plati- 
num(II) complexes 2-PtC12 (Jennerwein et al. 1989) and 
1-PtC12 (Wappes et al. 1984), the dextrorotatory enan- 
tiomer of the (+)-[1,2-bis-(2-hydroxyphenyl)ethylenedi- 
amine]dichloroplatinum(II) has the R,R [compound 
Table 1. IH-NMR data of [l,2-bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II) complexes and of their ligands [6 (ppm), 
tetramethylsilane (internal)] 
Compound Aromatic H CH (benzylic) NH OH OCH3 
(-)-3a" 6.75-6.86 (m, 4H) 4.46 (s, 2H) 1.70 (s, 4H) 3.79 (s, 6H) 
7.09-7.16 (m, 2 H) 
7.22-7.26 (m, 2 H) 
(+)-3a" 6.75-6.86 (m, 4H) 4.46 (s, 2H) 1.71 (s, 4H) 3.79 (s, 6H) 
7.09-7.16 (m, 2H) 
7.22-7.26 (m, 2 H) 
(-)-35 6.59-7.47 (m, 8H) 4.24 (s, 2H) 5.85 (s, br, 6H) 
(+)-35 6.62-7.49 (m, 8 H) 4.23 (s, 2H) 5.86 (s, br, 6H) 
(-)-3-PtClz c 6.57-6.63 (m, 2 H) 4.70 (br, 2 H) 5.27 (br, 2 H) 10.53 (s, 2H) 
6.85-6.89 (m, 2 H) 6.09 (br, 2 H) 
7.01-7.08 (m, 4 H) 
(+)-3-PtClz c 6.57-6.63 (m, 2 H) 4.70 (br, 2 H) 5.28 (br, 2 H) 10.53 (s, 2 H) 
6.83-6.89 (m, 2 H) 6.09 (br, 2 H) 
7.01-7.08 (m, 4 H) 
a 250 MHz, CDC13 
b 60 MHz, CDC13 
250 MHz, [Djdimethylformamide 
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~ CHN 
MeO HC CH ONe (-+1 1 I /  \ 
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Fig. 1.1H-NMR benzyl signals of ligands in CDC13 at 250 MHz in 
the presence of6.3 equivalents ofan optically active auxiliary and 
of a small amount of D20. Top: (4-)3a shows inglets for both en- 
antiomers. Centre: (+)3a shows one singlet only, i.e. an enantio- 
meric purity of approx. 100%. Bottom: (-)3a shows another sing- 
let, exclusively (i.e. purity approx. 100%) 
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Fig. 2. CD spectra of enantiomeric [1,2-bis(2-hydroxyphenyl)ethyle- 
nediamine]dichloroplatinum(II) complexes: (...) (-)-PtCI 2, (--) 
(+)-PtC12; ( - - )  UV spectrum 
(+)-3-PtC12] and the levorotatory enantiomer the S,S 
configuration [compound (-)-3-PtCI/] (Fig. 2). 
The CD spectrum of (-)-3-PtC12 as well as the spec- 
trum of (-)-I-PtC12 (Wappes et al./984) showed a neg- 
ative band at 380 nm with a value of about 0.16, which 
was assigned to the d~l* transition bands (Ito et al. 
1967). A comparison of these bands with that of ( - ) -  
(S, S)-dichloro[1,2-diphenylethylenediamine]platinum(II) 
suggested a predominant 5-gauche conformation of 
these complexes (Noji et al. 1984). Their mirror-image 
CD spectra imply a 2-gauche prevailing conformation 
(see Fig. 2). 
Conformational information for platinum(II) five- 
membered chelate rings can also be obtained from tH- 
NMR-spectra. In an earlier ~H-NMR study (Gust et al. 
1990) we had demonstrated that in [l-(2,6-dichloro-4-hy- 
droxyphenyl)-2-phenylethylenediamine]diiodoplatinum- 
(II) complexes the coupling constant between the ben- 
oM o\ HD 
(S,S) jP t .~  ( " -U)  
X-conformotiorl 
2Ms~ 
~- SO~ -j ~N __ 
6-conforrnation 
J~  
J 
JH_H=I2.L HZ 
5 4 
6 in ppm 
Fig. 3. 250-MHz 1H-NMR spectrum of the tetradeuterated (_+)-3- 
PtSO4 in [D6] DMSO. An AB pattern with a JH.a = 12.4 Hz indi- 
cates an angle between the H-C-C-H protons of about 180 ~ repre- 
senting the 5 conformation with predominantly equatorially 
oriented phenyl rings 
zylic protons possesses a Karplus-type angle dependence. 
Platinum complexes with threo-configurated ligands 
have stable conformations with equatorially orientated 
phenyl rings and a coupling constant JH-H = 12.2 HZ for 
the chemically non-equivalent benzylic protons. In the 
case of (+)-3-PtC1/this procedure could not be applied 
for conformation analysis, since the symmetrical com- 
plex gives only a single signal for both benzylic protons. 
This was overcome by using the sulfatoplatinum(II) de- 
rivative of (_)-3-PtC12. In dimethylsulfoxide (DMSO) as 
solvent one DMSO molecule and the SO4 residue coordi- 
nated to platinum. These two different leaving groups 
rendered the platinum(II) complex asymmetrical, giving 
rise to a diastereoisomeric splitting of the benzylic pro- 
tons in the tH-NMR spectra (compare Fig. 3). The sig- 
nals were also split by coupling with the amino protons. 
When the amino groups were tetradeuterated before dis- 
solution in [D6] DMSO the H-C-C-H protons gave an 
AB pattern with a Jn-n = 12.4 Hz, which indicated a di- 
hedral angle between the protons of about 180 ~ . This 
meant that the phenyl rings were predominantly equa- 
torially orientated in solution (5 conformation Fig. 3). A 
simultaneous presence of axially orientated phenyl rings 
was not observed. 
The structure discussed above was also found for 
(-)-3-PtClz in crystalline form. The X-ray structural 
Fig. 4. Molecular structure of (-)-3-PtC12 determined by X-ray dif- 
fraction analysis 
analysis of (-)-3-PtC12 is illustrated in Fig. 4. (-)-3- 
PtCI2 crystallized in the 5-gauche conformation with 
equatorially orientated phenyl rings. The aromatic rings 
were arranged with a dihedral angel of 70.13 ~ and both 
hydroxy groups placed above the five-membered chelate 
ring. The chelate ring is puckered with coordinated N 
atoms lying on the platinum coordination plane and with 
the benzylic C-atoms lying ___0.358 nm out of plane. 
From this crystal structure the S, S configuration can be 
assigned to (-)-3-PtClz. A detailed escription of these 
results is given in the following publication. 
Biology 
For characterization of the NIH:OVCAR-3 ovarian 
cancer cell line cytogenetic analysis and investigation of 
growth kinetics and of the sensitivity against therapeuti- 
cally used drugs were performed. 
The epithelial ovarian cancer cell line forms cobble- 
stone-like monolayers (Fig. 5). Several hours after con- 
fluence strikingly large vacuoles appear (Fig. 6). In addi- 
tion, it is noted that cultures left at confluence for ex- 
tended periods develop foci of"piled-up" cells. These foci 
seem morphologically more complex than simple mono- 
layers. The detection of mucin, glycogen and lipids by 
Mucicarmine, periodic acid/schiff and Sudan IV staining 
was unsuccessful. 
Fig. 5. Confluent NIH:OVCAR-3 cells in culture (41th passage). 
Typical cobblestone-like monolayer (phase contrast, 320 • ) 
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Fig. 6. Formation of intracellular vacuoles in an "over-confluent" 
culture of NIH:OVCAR-3 (passage 41, phase-contrast, 320 x ) 
The cytogenetic analysis demonstrated that the NI- 
H:OVCAR-3 line includes cells with a hypotriploid to a 
hypohexaploid karyotype (Fig. 7). The modal chromo- 
some number amounts to 63. A karyogram of the NIH:- 
OVCAR-3 cell line, which shows several characteristic 
chromosome anomalies, ispresented in Fig. 8. 
The morphological and cytogenetic haracteristic 
proved to be constant over 22 passages and an observa- 
tion period of about 30 weeks. 
Figure 9 A, B illustrates the growth curves and the cor- 
responding doubling times at any time of incubation for 
the NIH:OVCAR-3 cell line in the passages 24, 30, 32 
(A), and 37, 49 (B). Under the given experimental condi- 
tions the logarithmic phase covers only a small fraction 
of the overall growth curve (Skehan and Friedman 1984). 
In a plot of doubling time versus time of incubation, ex- 
ponential growth is characterized bya parallelism of the 
graphs with the x-axis. The NIH:OVCAR-3 cell line 
2~ 
21 
18 
15 
6 63 66 69 73 / 126 q31 
Chromosome number 
Fig.7. Chromosome distribution of N IH :OVCAR-3  cells. D, 29th 
passage from origin; I ,  51th passage from origin. The cells were pas- 
saged weekly. For each passage the chromosomes from 50 well- 
spread metaphase plates were counted 
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Fig. 8. Spread metaphase of NIH:OVCAR-3 cells (passage 26) with 
66 chromosomes; obvious chromosome anomalies: bicentric chro- 
mosomes, deletions on both arms (magnification 1200 x,  Giemsa 
chromosome staining) 
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Fig. 9. Growth curves and corresponding doubling times of the 
NIH:OVCAR-3 cell line as a function of the passage number. 
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microscopic field for passages 24, 30, 32, 37, 49 
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grows exponentially for a maximum of two generations. 
In the 24th passage the minimal doubling time of the cells 
amounts to 125 h, which is relatively long. In the follow- 
ing passages, however, the minimal doubling times ap- 
proximate a constant value of about 35 h. 
In order to gain information on the sensitivity of the 
NIH:OVCAR-3 cell line against the frequently used 
drugs cisplatin (Fig. 10A), 5-fluorouracil (Fig. 10B), 
Adriamycin (Fig. 10 C), melphalan (Fig. 10 D), and vin- 
""'~O 17 nM ~ 
1.7BM 
Adriamycin 
C 
I I I 
100 200 300 
h 
L) 
qD 
(D 
(3 
<> O.IMM o 
,oo 
X O.OlpM 
60 X O Melphalan 
",,4:>.o 
0 100 200 300 
h 
100< 
L) 
60 
L) 
L_ 
~ 20 i Vinblastin~~ 0 /o.  
100 200 300 
h 
Fig. 10. Effect of cisplatin (A), 
5-fluorouracil (B), Adriamycin 
(C), melphalan (D) and vinblastine 
(E) on the proliferation of NIH: 
OVCAR-3 ovarian cancer cells. 
Plot of corrected T/C values 
versus time of drug exposure. 
Inoculum: 100 ~tl/welt a a density 
of 28 cells (24th passage)/ 
microscopic field; preincubation 
48 h; drug incubation 304 h 
blastine (Fig. 10E), the cells were incubated with these 
compounds at therapeutically relevant concentrations 
for 304 h. 
Only at the highest concentration (1 ~tM) did cisplatin, 
the most active drug in the therapy of ovarian cancer, 
show a cytocidal effect, which we consider essential for a 
curative effect in vivo. It is important, however, that the 
NIH:OVCAR-3 cells are in contact with this drug for a 
relatively long period in order to kill the cells (compare 
part III of this publication series). Owing to the marked 
toxic side-effects and the pharmacokinetics of cisplatin it 
is difficult to meet this demand in vivo. 
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Adriamycin (Fig. 10C) and melphalan (Fig. 10D), 
which are used in combination with cisplatin in the ther- 
apy of the advanced ovarian cancer, showed no eytocidal 
activities in the concentrations u ed. Our results with 
Adriamycin, cisplatin and melphalan are in accordance 
with those of Hamilton et al. (1983), who also describe a
resistance of the NIH:OVCAR-3 cell line against hese 
drugs. 5-Fluorouracil, which is reported to act synergisti- 
cally with cisplatin in a human ovarian cancer cell line 
(Scanlon et al. 1986), showed cytocidal activity in our ex- 
periment only at the highest concentration (1gM). A 
clinical study in a group of previously untreated patients, 
however, demonstrated a lower activity of 5-fluorouracil 
in comparison to melphalan (Smith and Ruthledge 1975; 
compare Omura 1989). 
Among the five common drugs tested on the NIH:OV- 
CAR-3 cell line vinblastine proved to be the most 
active one. At the very low concentration of I nM 
vinblastine initially leads to a complete inhibition of cell 
proliferation. However, after 100 h the cells recover from 
the initial damage (Fig. 10E). By increasing the con- 
centration to 10 nM a cytocidal effects is brought about. 
Though in vitro data sh.ow vinblastine to be one of the 
most active drugs against ovarian cancer, it is ineffective 
as "salvage" therapy (Surwit et al. 1987). 
In preliminary experiments we could show that at a 
concentration of 2.5 BM (duration of drug incubation 
256 h) the enantiomeric [1,2-bis(2-hydroxyphenyl)ethyle- 
nediamine]dichloroplatinum(II) complexes (+)-3-PtClz 
and (-)-3-PtC12 produce qual effects (T/C~orr = 10%) 
on the NIH:OVCAR-3 cell line. However, a difference 
between the enantiomers regarding the inhibition kinetics 
was seen. For (-)-3-PtC12 a faster onset of the cytoeidal 
effect was detected. These experiments will be described 
in detail in part IlI of this communication. 
Discussion 
In part I of this publication series we have described the 
synthesis and testing of [( _+ )-l,2-bis(2-hydroxyphenyl)- 
ethylenediamine] dichloroplatinum (II) [( • )-3-PtC12] , 
which proved to be a very promising new platinum com- 
plex for the therapy of cisplatin-resistant ovarian cancer 
(Mfiller et al. 1990). In order to improve the antitumor 
activity of (+_)-3-PtClz a resolution into the optically ac- 
tive forms [(+)- and (-)-3-PtC12] was attempted (com- 
pare Scheme 2). This was achieved at the stage of the 
(+)-I,2-bis(2-methoxyphenyl)ethylenediamine (3a) by 
fractional crystallization of the diastereoisomeric salts of 
3a with optically active tartaric acid in EtOH. The com- 
plete enantiomeric purity of (+)-3a and (-) -3a could be 
proved by 1H-NMR spectroscopy using (S)-(+)- 1-O-an- 
thryl)-2,2,2-trifluoroethanol s the optically active sol- 
vent (see Fig. 1). After ether cleavage of the enantiomeric 
methoxy compounds [(+)-3a nd (--)-3a] [(+)- and ( - ) -  
1,2-bis(2-hydroxyphenyl)ethylenediamine]dichloroplati- 
num(II) [(+)- and (-)-3- PtC12] were obtained by reac- 
tion with KzPtC14 (Scheme 2). The absolute configura- 
tion of the enantiomers (+)-3-PtClz (R,R) and (-)-3- 
PtC12 (S,S) was determined by CD spectroscopy (Fig. 2). 
As substances for comparison, (R,R)- and (S,S)-di- 
chloro(1,2-diphenylethylenediamine)platinum(II) were 
used. 
1H-NMR spectroscopic studies, which were per- 
formed with N,N,N',N~-tetradeuterated [(• 
hydroxyphenyl)ethylenediamine]sulfatoplatinum(II) 
[+_)-3-PtSO4] dissolved in [D6]DMSO, gave insight into 
the conformation of (_+)-3-PtCI2. On dissolution in 
[D6]DMSO (+_)-3-PtSO4 forms an asymmetric complex, 
in which both SOl- and DMSO are coordinated toplati- 
num. This Pt(DMSO)(SO#) derivative shows a diaste- 
reoisomeric splitting of the non-equivalent benzylic pro- 
tons in the INMR spectrum giving an AB pattern with a 
Jn-n = 12.4 Hz (Fig. 3). This dihedral angle between the 
two protons amounts to about 180 ~ which signifies an 
axial orientation of the the two protons and two equato- 
rial phenyl rings (6 conformation i Fig. 3). The same 
three-dimensional structure is observed by X-ray struc- 
tural analysis, which also confirms the S,S configuration 
of (-)-3-PtC12 (Fig. 4). For the evaluation of the enantio- 
meric [l,2-bis(2-hydroxyphenyl)ethylenediamine]dichlo- 
roplantinum(II) complexes [(+)- and (-)-3- PtClz] the 
human ovarian cancer cell line NIH:OVCAR-3, which is 
described to be resistant againstcisplatin a d other stan- 
dard drugs (Hamilton et al. 1983), was used as test model. 
In order to recognize ven small differences inactivity we 
studied the drug-induced changes in cell proliferation ki- 
netics. For this purpose we applied a computer-aided 
microtechnique that allows the registration of growth 
curves of the NIH:OVCAR-3 cells in monolayer cultures 
by large-scale spectrophotometric measurements after 
crystal violet staining using 96-well microtitration plates 
(Reile et al. 1990). The NIH:OVCAR-3 cell line was char- 
acterized by cytogenetic analysis (Fig. 7 and 8), by its 
growth kinetics (Fig.9) and by its sensitivity against 
therapeutically used drugs (Fig. 10). The last-mentioned 
experiments confirmed thelow sensitivity of theNIH:- 
OVCAR-3 cell line against therapeutically relevant 
concentrations of cisplatin, Adriamycin and melphalan 
described by Hamilton et al. (1983). It is of interest that 
5-fluorouracil (cytocidal at i gM) and especially vinblas- 
tine (cytocidal at 10 riM) produce amarked inhibition of 
the NIH:OVCAR-3 cell line in concentrations that can be 
achieved under in vivo conditions. 
In clinical studies, however, the superiority of 5- 
fluorouracil and vinblastine compared to cisplatin, 
Adriamycin and melphalan in the therapy of ovarian 
cancer was not confirmed (Omura 1989; Surwit et al. 
1987). 
Two mechanisms responsible for the multidrug resis- 
tance phenotype in ovarian cancer are discussed (com- 
pare Ozols et al. 1989): 
1. The ability of the malignant cell to synthesize a mem- 
brane glycoprotein (P-170), which is part of a complex 
system counteracting the drug accumulation in the 
cancer cell. By this mechanism structurally unrelated 
chemotherapeutic agents, e.g. Vinca lkaloids and Adria- 
mycin, are transported out of the cell. 
2. The ability of the malignant cell to elevate its content 
of glutathione, which inactivates drugs that react with 
nucleophilic targets of the tumor cell (e.g. DNA). This 
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mechanism is consistent with the observed cross-resis- 
tance between cisplatin and alkylating agents like mel- 
phalan 1. 
Further preclinical studies with 5-fluorouracil and 
vinblastine will be required to evaluate their usefulness in 
the treatment of  ovarian cancer. 
The experiments with enantiomeric [l,2-bis- 
(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II) 
complexes [(+)-  and (-)-3-PtC12] on the N IH:OVCAR 3 
cell line revealed no differences concerning the maxi- 
mum antitumor effect. At a concentration of  2.5 I.tM 
both enantiomers produce T/C .... values of  about 
- 10%. With (-) -3-PtC12, however, a faster onset of  the 
cytocidal effect was detectable. 
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